<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7443335\results\search\drug\results.xml">
  <result pre="been proposed such as lopinavir/ritonavir (400/100Â mg every 12Â h)," exact="chloroquine" post="(500Â mg every 12Â h), and hydroxyl-chloroquine (200Â mg"/>
  <result pre="given treatment of FPV and 45 patients were treated with" exact="lopinavir" post="and ritonavir (LPV/RTV) combination. It was found that those"/>
  <result pre="of FPV and 45 patients were treated with lopinavir and" exact="ritonavir" post="(LPV/RTV) combination. It was found that those treated with"/>
  <result pre="the attention, such as ribavirin, favipiravir, oseltamivir and umifenovir [44]." exact="Ribavirin" post="(Tribavirin) is a broad-spectrum guanosine analogue against RNA and"/>
  <result pre="and DNA viruses such as hepatitis C and E [45]." exact="Ribavirin" post="in conjunction with interferon showed synergistic activity in in"/>
  <result pre="activity in in vitro antiviral study. This result suggested that" exact="ribavirin" post="elicits antiviral activity at lower concentration with interferon. Therefore,"/>
  <result pre="concentration with interferon. Therefore, a combination therapy of interferon and" exact="ribavirin" post="were widely used due to synergistic effect. Simultaneous use"/>
  <result pre="sputum specimens remain negative for more than three times [46]." exact="Chloroquine" post="and hydroxychloroquine (HC) had received intense attention because of"/>
  <result pre="remain negative for more than three times [46]. Chloroquine and" exact="hydroxychloroquine" post="(HC) had received intense attention because of viral enzymes"/>
  <result pre="events and other potential side effects. The potential benefits of" exact="chloroquine" post="and HC no longer outweigh the potential risks for"/>
  <result pre="risks for the authorized use [47]. HC is superior to" exact="chloroquine" post="and reported positive results in some pre-clinical data in"/>
  <result pre="of severity [48]. Philippe Gautret et al. conducted study on" exact="hydroxychloroquine" post="and azithromycin as a treatment toCOVID-19. It was found"/>
  <result pre="[48]. Philippe Gautret et al. conducted study on hydroxychloroquine and" exact="azithromycin" post="as a treatment toCOVID-19. It was found that patients"/>
  <result pre="a treatment toCOVID-19. It was found that patients treated with" exact="hydroxychloroquine" post="showed significant reduction in viral infection as compared to"/>
  <result pre="significant reduction in viral infection as compared to the control." exact="Hydroxychloroquine" post="in combination with azithromycin were more effective in the"/>
  <result pre="infection as compared to the control. Hydroxychloroquine in combination with" exact="azithromycin" post="were more effective in the elimination of virus [49]."/>
  <result pre="Magagnoli et al. conducted study to study the outcomes of" exact="hydroxychloroquine" post="in COVID-19 patients. This study was carried out on"/>
  <result pre="pandemic. Anticoagulants like Vitamin K antagonists, dabigatran, apixaban, betrixaban, edoxaban," exact="rivaroxaban" post="and antiplatelets like clopidogrel, prasugrel ticagrelor, cilostazol may have"/>
  <result pre="apixaban, betrixaban, edoxaban, rivaroxaban and antiplatelets like clopidogrel, prasugrel ticagrelor," exact="cilostazol" post="may have interactions with COVID âˆ’19 investigational drug. Therefore,"/>
  <result pre="produce inhalable SLMs with stealth effect and deep lung deposition," exact="cisplatin" post="microcrystals were prepared by high pressure homogenization (HPH) in"/>
  <result pre="PEGylated components (DSPE-methyl-PEG conjugate-2000, DSPE-mPEG-2000) or D-Î±-Tocopherol polyethylene glycol 1000" exact="succinate" post="(TPGS) via spray-drying technique. SLMs was explained by the"/>
  <result pre="technique. SLMs was explained by the increased solubilization of un-entrapped" exact="cisplatin" post="microcrystals on SLM surface by PEGylated fractions leading to"/>
  <result pre="or use at targeted site. Joshy et al. reported the" exact="zidovudine" post="loaded polyvinylpyrrolidone (PVP)/stearic acid (SA)-polyethylene glycol (PEG) nanoparticles led"/>
  <result pre="anti-SARS or anti-MARS reagents based on Ag2S NCs [148] 4" exact="Amantadine" post="(Ada), on the outermost layer of PVPâ€&quot;PEG-coated silver nanorods"/>
  <result pre="cytotoxic lymphocytes to produce around eightfold stronger tumor necrosis factor" exact="alpha" post="in vivo Surface modifications of nanomaterials in fundamentally improving"/>
  <result pre="viral protein Nontoxic drug-loaded nanoaggregates inhibit HCV replication at low" exact="camptothecin" post="concentration. [152] 8 Modified dendrimer NPs Venezuelan equine encephalitis"/>
  <result pre="2020). 47Coronavirus (COVID-19) update: FDA revokes emergency use authorization for" exact="chloroquine" post="and hydroxychloroquine|FDA, (n.d). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed August 10, 2020). 48PooladandaV.ThatikondaS.GoduguC.The"/>
  <result pre="potential therapeutic options to combat COVID-19Life Sci.254202011776510.1016/j.lfs.2020.117765 49GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: preliminary results of an"/>
  <result pre="preliminary results of an open-label non-randomized clinical trialMedRxiv.202010.1101/2020.03.16.200371352020.03.16.20037135 50MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ.W.SuttonS.S.AmbatiJ.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19MedRxiv.202010.1101/2020.04.16.200659202020.04.16.20065920 51COVID-19"/>
  <result pre="rodents using large porous particlesAerosol Sci. Technol.32200042143310.1080/027868200303551 71LevetV.RosiÃ¨reR.MerlosR.FusaroL.BergerG.AmighiK.WauthozN.Development of controlled-release" exact="cisplatin" post="dry powders for inhalation against lung cancersInt. J. Pharm.515201620922010.1016/j.ijpharm.2016.10.01927737810"/>
  <result pre="vaccineViral Immunol.312018475410.1089/vim.2017.002429328884 152LancelotA.ClaverÃ­a-GimenoR.VelÃ¡zquez-CampoyA.AbianO.SerranoJ.L.SierraT.Nanostructures based on ammonium-terminated amphiphilic Janus dendrimers as" exact="camptothecin" post="carriers with antiviral activityEur. Polym. J.90201713614910.1016/j.eurpolymj.2017.03.012 153ChahalJ.S.FangT.WoodhamA.W.KhanO.F.LingJ.AndersonD.G.PloeghH.L.An RNA nanoparticle"/>
  <result pre="virus infectionsMater. Sci. Eng. C.89201841342110.1016/j.msec.2018.04.005 157KumarP.LakshmiY.S.KondapiA.K.Triple drug combination of Zidovudine," exact="Efavirenz" post="and lamivudine loaded Lactoferrin nanoparticles: an effective Nano first-line"/>
  <result pre="Sci. Eng. C.89201841342110.1016/j.msec.2018.04.005 157KumarP.LakshmiY.S.KondapiA.K.Triple drug combination of Zidovudine, Efavirenz and" exact="lamivudine" post="loaded Lactoferrin nanoparticles: an effective Nano first-line regimen for"/>
 </snippets>
</snippetsTree>
